A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

December 10, 2025

Study Completion Date

June 10, 2026

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

IMC-002 + SOC

intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg

DRUG

Placebo + SOC

intravenous injection of Placebo

All Listed Sponsors

lead

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

OTHER

NCT06535412 - A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter